Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-year open-label extension study of odanacatib in postmenopausal osteoporosis
2005-001511-22Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of odanacatib in postmenopausal osteoporosis (5 arms), sponsored by Merck & Co. Primary endpoint: Percent change from baseline in lumbar spine bone mineral density. Started Jul 2005; status: completed.
02
Drugs
odanacatib
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2005-001511-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001511-22.